Senior Credit Analyst, Lucror Analytics

Trung Nguyen

Senior Credit Analyst

High Yield Experts

Lucror Analytics

Lucror Analytics is a leading credit and ESG research specialist and a provider of technology solutions for differentiated fixed income strategies. Our roots are in bottom-up fundamental credit analysis with a specialization in high yield corporate credits from Europe, Asia and Latin America. We are one of few research specialists integrating ESG considerations with fundamental credit research through a dedicated ESG platform. Our ESG assessment covers five key criteria: Disclosure, E,S, & G Pillars, Controversies, ESG Impact on Credit and ESG Momentum.

Recognizing the importance and value-add of Factor Investing in fixed income, Lucror developed the Smart Quant Navigator (SQN), an intuitive platform that helps clients devise and implement factor-based strategies ranging from pure quant to active fundamental, with integrated ESG.

Our company has been at the forefront of developments in the fixed income markets, identifying opportunities and consistently delivering new products and value-adding solutions to clients. Lucror has close relationships with the largest and most reputable asset managers, family offices, hedge funds, investment and wealth managers globally.

Credit

<ul>
<li>In today's Morning Views publication we comment on developments of the following high yield issuers: Biocon Biologics</li>
<li>Overnight, US bond yields fell as traders anticipated fresh data to guide Fed policy. The 10-year Treasury yield slipped amid expectations of a potential rate cut. US equity was flattish.</li>
<li>The October CPI and core CPI numbers will be released today. The prolonged US government shutdown could delay the October and November jobs data to early December, potentially resulting in the weakest nonfarm payrolls since 2020.</li>
</ul>


In today's Morning Views publication we comment on developments of the following high yield issuers: Biocon Biologics
Overnight, US bond yields fell as traders anticipated fresh data to guide Fed policy. The 10-year Treasury yield slipped amid expectations of a potential rate cut. US equity was flattish.
The October CPI and core CPI numbers will be released today. The prolonged US government shutdown could delay the October and November jobs data to early December, potentially resulting in the weakest nonfarm payrolls since 2020.


<ul>
<li>In today's Morning Views publication we comment on developments of the following high yield issuers: Biocon Biologics, Tata Motors, ReNew Energy</li>
<li>US treasury yields rose for a second day, with the curve steepening despite good overall demand for an auction of 20Y notes. The yield on the 2Y UST rose 2 bps to 3.97%, while that on the 10Y UST was up 5 bps at 4.45%.</li>
<li>Equities advanced on news that Iran was asking Gulf states to mediate a ceasefire with Israel. The S&amp;P 500 increased 0.9% to 6,033, while the Nasdaq climbed 1.5% to 19,701.</li>
</ul>


In today's Morning Views publication we comment on developments of the following high yield issuers: Biocon Biologics, Tata Motors, ReNew Energy
US treasury yields rose for a second day, with the curve steepening despite good overall demand for an auction of 20Y notes. The yield on the 2Y UST rose 2 bps to 3.97%, while that on the 10Y UST was up 5 bps at 4.45%.
Equities advanced on news that Iran was asking Gulf states to mediate a ceasefire with Israel. The S&amp;P 500 increased 0.9% to 6,033, while the Nasdaq climbed 1.5% to 19,701.


<ul>
<li>Biocon Limited's Q4 and FY 2024-25 results were solid in our view, with robust growth, stable profitability, as well as improved working capital and cash flows.</li>
<li>The balance sheet has strengthened, and liquidity is adequate.</li>
</ul>


Biocon Limited's Q4 and FY 2024-25 results were solid in our view, with robust growth, stable profitability, as well as improved working capital and cash flows.
The balance sheet has strengthened, and liquidity is adequate.


Biocon Biologics - Earnings Flash - Q4 And FY 2024-25 Results - Lucror Analytics

Leonard Law, CFA

<ul>
<li>In today's Morning Views publication we comment on developments of the following high yield issuers: China Jinmao, West China Cement, Biocon Biologics</li>
<li>UST yields declined yesterday, led by the front end, following the Fed’s 25-bp rate cut and announcement that it will commence T-bill purchases. The UST curve bull steepened sharply, with the yield on the 2Y UST falling 8 bps to 3.54%, while the yield on the 10Y decreased 4 bps to 4.15%.</li>
<li>Fed-dated OIS continued to price in two rate cuts in 2026 (one before June and another by October), despite the FOMC’s dot plot indicating just one cut for 2026. Equities climbed, with the S&amp;P 500 rising 0.7% to 6,887.</li>
</ul>


In today's Morning Views publication we comment on developments of the following high yield issuers: China Jinmao, West China Cement, Biocon Biologics
UST yields declined yesterday, led by the front end, following the Fed’s 25-bp rate cut and announcement that it will commence T-bill purchases. The UST curve bull steepened sharply, with the yield on the 2Y UST falling 8 bps to 3.54%, while the yield on the 10Y decreased 4 bps to 4.15%.
Fed-dated OIS continued to price in two rate cuts in 2026 (one before June and another by October), despite the FOMC’s dot plot indicating just one cut for 2026. Equities climbed, with the S&amp;P 500 rising 0.7% to 6,887.


<ul>
<li>In today's Morning Views publication we comment on developments of the following high yield issuers: Vedanta Resources, Xiaomi Corp, Reliance Industries, Biocon Biologics</li>
<li>UST yields climbed 4 bps across the curve on Friday, in tandem with a decline in Canadian government bonds, even though the belatedly-released September PCE inflation numbers were line with estimates.</li>
<li>Yields on the 2Y and 10Y USTs rose to 3.56% and 4.14%, respectively. Equities notched small gains towards October’s record-high levels, with the S&amp;P 500 and Nasdaq up 0.2% and 0.3%, respectively.</li>
</ul>


In today's Morning Views publication we comment on developments of the following high yield issuers: Vedanta Resources, Xiaomi Corp, Reliance Industries, Biocon Biologics
UST yields climbed 4 bps across the curve on Friday, in tandem with a decline in Canadian government bonds, even though the belatedly-released September PCE inflation numbers were line with estimates.
Yields on the 2Y and 10Y USTs rose to 3.56% and 4.14%, respectively. Equities notched small gains towards October’s record-high levels, with the S&amp;P 500 and Nasdaq up 0.2% and 0.3%, respectively.


India

Biocon Biologics India Limited of India operates as a biopharmaceutical company. The Company offers prevention, alleviation, and treatment for chronic diseases such as diabetes, oncology, cancer, and autoimmune diseases. Biocon Biologics India serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Biocon Biologics India (1777628D IN)

Lucror Analytics - Morning Views Asia

In today's Morning Views publication we comment on developments of the following high yield issuers: Biocon Biologics Overnight, US bond yields...

Lucror Analytics

Lucror Analytics - Morning Views Asia

In today's Morning Views publication we comment on developments of the following high yield issuers: Biocon Biologics, Tata Motors, ReNew Energy

Lucror Analytics

Biocon Biologics - Earnings Flash - Q4 And FY 2024-25 Results - Lucror Analytics

Biocon Limited's Q4 and FY 2024-25 results were solid in our view, with robust growth, stable profitability, as well as improved working...

Lucror Analytics

Lucror Analytics - Morning Views Asia

In today's Morning Views publication we comment on developments of the following high yield issuers: China Jinmao, West China Cement, Biocon Biologics

Lucror Analytics

Lucror Analytics - Morning Views Asia

In today's Morning Views publication we comment on developments of the following high yield issuers: Vedanta Resources, Xiaomi Corp, Reliance...

Lucror Analytics

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)